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Abstract
Background: Patients with juvenile idiopathic arthritis (JIA) on non-steroidal anti- inflammatory drugs (NSAIDs) may
experience abdominal pain. In adults, NSAID use has been linked to an increase in fecal calprotectin (FC) levels, a
surrogate marker for gut inflammation. In JIA, data on gut inflammation related to drug use is scarce.
Methods: JIA patients followed up at the outpatient pediatric rheumatology clinic in Children’s Hospital, Helsinki
University Hospital, Helsinki, Finland were routinely assessed for FC if they complained about abdominal pain, had
an elevated erythrocyte sedimentation rate (ESR) or used NSAIDs on a daily basis. The FC levels were related to the
presence of abdominal pain, to ESR, and to the presence of HLA-B27.
Results: Of the total group of 90 patients (median age 9.1 years; 45 JIA patients with disease modifying anti-
rheumatic drugs (DMARDs), 25 without DMARD medication, and 20 arthralgia patients as controls), approximately
50% used NSAIDs, of whom 40% complained about abdominal pain. In patients with abdominal pain, one-third
had elevated FC values (>100 μg/g). The FC values, for the most part, declined along with the discontinuation or
reduction of NSAIDs and after intensifying the DMARD medication, where after the pain disappeared. In patients
with an elevated ESR, the FC values and ESR normalized in parallel. The presence of HLA-B27 was not associated
with FC levels.
Conclusion: In patients with JIA and abdominal pain, it may be useful to determine the FC when evaluating the
need for further gastrointestinal examinations.
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Background
In patients with juvenile idiopathic arthritis (JIA), a
chronic joint inflammation of childhood, non-steroidal
anti-inflammatory drugs (NSAIDs) are frequently needed.
When the disease activity is low, NSAIDs can be used as a
monotherapy for up to two months [1]. However, it has
been reported that JIA patients may experience abdominal
pain related to NSAID use [2]. NSAIDs may cause intes-
tinal damage in adults [3], but there are less data about
children [4, 5]. The differential diagnosis of abdominal
symptoms, however, is challenging. On the other hand, a
considerable proportion of patients with inflammatory
bowel disease (IBD) may have joint pains [6, 7].
To assess the presence of inflammation in the gut in de-
tail, endoscopy is needed. However, especially in children
this procedure is challenging; it is invasive and has to be
performed under anesthesia. Thus, during recent years,
the use of surrogate markers of gut inflammation, such as
fecal calprotectin (FC), has emerged as a valuable screen-
ing tool [8–12]. In active IBD, the correlation between the
endoscopy results and FC levels is good [9–11, 13].
Several reports have shown that NSAID use in adults may
result in an increase in FC levels, reflecting intestinal
inflammation, and furthermore, the FC levels decline
when the drug is discontinued, suggesting healing of the
gut mucosa [14].
Calprotectin, a major cytosolic protein released during
the activation of neutrophils, is a relatively new marker for
inflammatory processes in the endothelium [15]. An
increase in the serum calprotectin level is seen in several
inflammatory conditions, including JIA [16]. Calprotectin
is stable in feces, and fecal concentrations reflect not only
colonic inflammation, but the presence of small bowel
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involvement as well [9, 10]. FC levels are high among
patients with active IBD, providing a diagnostic tool for
differentiating between recurrent abdominal pain and
chronic inflammatory disease in the intestine [11, 12, 17]
and reducing the need of referrals for further investiga-
tions [18]. The significance of minor elevations in FC
levels is poorly understood, but dysfunctional pain is not
related to FC values [12]. Constipation may be associated
with a slight elevation in FC values [19].
In patients with JIA, data on the performance of FC
levels in the assessment of intestinal inflammation are
limited. At our hospital, we have routinely used FC mea-
surements for several years to screen for the presence of
gut inflammation in paediatric patients with non-specific
abdominal symptoms, e.g. abdominal pain. The aim of
this study was to evaluate the usefulness of FC measure-
ments in patients with JIA associated with NSAID use
and abdominal pain.
Methods
A group of 90 patients followed up at the outpatient
clinic of pediatric rheumatology in Children’s Hospital,
Helsinki University Hospital, Helsinki, Finland, a tertiary
care hospital, were routinely assessed for FC when they
complained about abdominal pain, had an elevated
erythrocyte sedimentation rate (ESR) or used NSAIDs
on a daily basis. Of the 90 patients, 50 had JIA for at
least 6 months, 20 patients had newly diagnosed JIA
(Table 1). As controls we had 20 patients with arthralgia
who were referred to our hospital for evaluation of JIA
(Table 1). No patients with systemic-onset JIA were
included and there were no patients with psoriasis or
undifferentiated arthritis.
JIA diagnosis was based on the criteria of the
International League of Associations for Rheumatology
(ILAR) [20]. At the time of JIA diagnosis, the presence
of HLA-B27, serum antinuclear antibodies (S-ANA)
and rheumatoid factor were routinely determined. The
disease was considered active (Table 1) if there were
active joints in the clinical examination and the doctor’s
global assessment of the disease using a visual analogue
scale (VAS) was > 1 (range 0–10) or if the ESR was
higher than 20 mm/h, which is comparable to a JIA
disease activity score of JADAS10 > 2 [21].
Fecal calprotectin (FC)
The FC levels were analyzed using a quantitative, enzyme-
linked immunoassay (PhiCal Test, Calpro AS, Oslo,
Norway) in routine analyses of the central laboratory
services of the Helsinki University Hospital. The fecal
samples were stored at –20°C until analyzed. FC values
<100 μg/g in the stools were considered normal and
values <50 μg/g very low, whereas values >1000 mg/g
were found to be exceedingly high [22–24]. Measure-
ments of FC levels were made on clinical grounds, i.e.
when the patient complained of abdominal pain or had an
elevated ESR or was using NSAIDs on a daily basis.
Elevated FC levels were controlled at regular follow-up
visits until normal.
Endoscopies were performed when the FC value was
> 200-300 μg/g. When the FC value was only mildly or
moderately elevated with no major symptoms, NSAIDs
were discontinued.
Statistical analyses
Data are presented as means (± standard deviation), or
as ranges and medians, as appropriate. Correlations be-
tween the parameters were calculated using either a
Spearman rank correlation, the Kruskall-Wallis test, or
logistic regression (with a threshold of elevated FC value
<100 μg/g or <50 μg/g), when appropriate and statistical
comparisons between groups were performed using the
Student’s t-test (normal distribution) or the Mann-
Whitney U test. Statistical analyses were performed
using Microsoft® software Excel 2010 or with IBM® SPSS®
Statistics 19 software. A p-value <0.05 was considered
significant.
Results
FC values in the patients
Of the 70 patients with JIA, 45 (64%) were on DMARD
medication (Table 1). In these 45 patients, FC values
ranged from 1 to 1617 μg/g (Table 2): ten (22%) had
elevated FC values (>100 μg/g), six had FC values be-
tween 50 and 100 μg/g, and 29 had FC values less
Table 1 Clinical characteristics of the patients; 70 having the JIA
diagnosis and 20 arthralgia
All patients
n = 90
Oligo
n = 33
Poly
n = 29
JSpA
n = 8
All JIA
n = 70
Arthralgia
n = 20
Age 10.2 ± 3.8 8.1 ± 3.5 11.8 ± 3.0 9.6 ± 3.9 8.7 ± 4.9
Female 25 (57%) 19 (43%) 0 44 (63%) 13 (65%)
ANA-Ab + 4 (12%) 6 (21%) 0 9 (13%) 1 (5%)
Anaemia 10 (30%) 9 (31%) 3 (38%) 22 (31%) 1 (5%)
HLA-B27 + 9 (27%) 6 (21%) 7 (88%) 22 (31%) 5 (25%)
Active disease 8 (24%) 9 (31%) 0 17 (24%) 0
NSAID + 15 (45%) 14 (48%) 5 (63%) 34 (49%) 12 (60%)
DMARD + 20 (61%) 20 (69%) 5 (63%) 45 (64%) 0
Biologicals + 3 (10%) 2 (7%) 0 5 (7%) 0
JIA juvenile idiopathic arthritis
Oligo juvenile oligoarthritis, Poly juvenile polyarthritis (RF-negative), JSpA juvenile
spondyloarthritis (including enthesitis related arthritis)
ANA-Ab antinuclear antibodies
DMARD disease-modifying anti-rheumatic drug
mainly methotrexate (MTX), other DMARDS: leflunomide, sulphasalazine (SSZ),
hydroxychloroquine, cyclosporine A (CyA)
- Ten patients had ≥1 DMARD (usually MTX + SSZ), one patient had CyA
with SSZ
NSAID non-steroidal anti-inflammatory drug
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than 50 μg/g. JIA patients with DMARDs had significantly
more often a FC value > 50 μg/g than patients without
DMARDs (p = 0.029). Of the 20 arthralgia patients
(Table 2) one (5%) with abdominal pain had a mildly ele-
vated FC value of 113 μg/g (Fig. 2) which returned to nor-
mal two months later. Twelve patients with arthralgia
used NSAIDs on a daily basis.
Of the ten JIA patients on DMARDs and with elevated
FC values, seven presented with abdominal pains
(Tables 2 and 3, Fig. 1) and five used NSAIDs on a regu-
lar basis. Three patients underwent endoscopies. One of
them had an exceedingly high FC value (1617 μg/g). This
particular patient reported abdominal pain, and after
medication for endoscopy-confirmed esophagitis with a
proton pump inhibitor (PPI) and dietary adjustment, her
pains disappeared and the FC value declined after three
months. Two other patients underwent endoscopies be-
cause of abdominal pain and elevated FC values (both
with values > 200 μg/g). In these two, biopsy findings
revealed mild gastritis and irritation in the bowel but
no pathological changes in the capsule endoscopy of
the small intestine. Naproxen was discontinued, and
abdominal pain subsequently disappeared in both patients.
FC-values normalized in two to three months.
The remaining seven JIA patients using DMARDS
and with FC values >100 μg/g (all with values less
than 200 μg/g) did not undergo endoscopies (Tables 2
and 3). Of these patients, two suffered from constipa-
tion. After successful treatment of constipation, their
FC values fell within normal ranges. The five other
patients were advised to take NSAIDs only for short
periods when they used NSAIDs on daily bases. Their
FC values returned to normal after restricting NSAID
use in all except one. In this particular patient, the
FC values fluctuated between 89 and 181 μg/g during
the follow-up even when he was not on NSAIDs. He
also had a diagnosis of IgA deficiency and auto-
immune (AI) hepatitis.
FC values were between 50 and 100 μg/g in six JIA
patients with DMARDs, of whom three suffered from
abdominal pain. These three had an active joint disease
and used NSAIDs regularly. Several months later, one of
them had an even higher FC value, 258 μg/g, but after
reducing the amount of NSAIDs he was taking and
increasing the dosage of DMARDs his abdominal pain
disappeared, and the FC value declined to normal after
two months. Similarly, when the joint disease of the
other two patients was better controlled, the patients’
need for NSAIDs decreased, and the FC values fell below
50 μg/g also after three to four months.
Twenty-five patients with JIA were not on DMARDS,
and the majority (n = 20) of them had a disease duration
of less than 6 months. The FC values ranged from 2 to
Table 2 Diagnoses of the patients and proportion of patients
with abdominal pain, NSAID usage, and their ESR and FC values
All patients
(n = 90)
Abdominal
pain
n (%)
NSAID
usage
n (%)
ESR mm/h
range (median)
elevated (n)
FC μg/g
range (median)
elevated (n)
JIA patients
Oligoarthritis
(33)
13 (39%) 15
(45%)
1–80 (12)
n = 15
1–368 (17)
n = 5
Polyarthritis (29) 11 (38%) 14
(48%)
1–94 (16)
n = 15
2–1617 (34)
n = 7
JSpA* (8) 1 (13%) 5 (63%) 10–35 (19)
n = 4
11–184 (18)
n = 1
All JIA (70) 27 (39%) 34
(70%)
1–94 (15)
n = 34 (49%)
1–1617 (25)
n = 13 (19%)
Arthralgia (20) 12 (60%) 12
(60%)
7–50 (10)
n = 7 (35%)
0–113 (32)
n = 1 (5%)
JIA juvenile idiopathic arthritis
*JSpA juvenile spondylarthritis
NSAID non-steroidal anti-inflammatory drug
ESR erythrocyte sedimentation rate
FC fecal calprotectin, cut-off of 100 μg/g for elevated values [17–19]
Table 3 FC-values of the JIA patients in relation to their abdominal
pain, NSAID usage, and ESR values
All JIA patients
(n = 70)
Abdominal
pain
NSAID
usage
elevated ESR
>20 mm/h
FC 0–50 μg/g (n = 51) 38% 43% 41%
FC 50–100 μg/g (n = 6) 50% 83% 83%
FC 100–200 μg/g (n = 10) 50% 60% 70%
FC > 200 μg/g (n = 3) 100% 67% 67%
JIA juvenile idiopathic arthritis
NSAID non-steroidal anti-inflammatory drug
ESR erythrocyte sedimentation rate
FC fecal calprotectin
Fig. 1 JIA patients with elevated FC-values and/or regular NSAID use
and/or abdominal pain. Of the 70 patients with JIA 48 had elevated
FC value and/or NSAID use and/or abdominal pain. The numbers in
overlapping areas show the combinations e.g. JIA patients having
both abdominal pain and elevated FC values (n = 8), and four of
them used NSAIDs as regular bases. See the text for other details
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189 μg/g (Fig. 1, Table 3). Of the 25 patients three (12%)
had elevated values (>100 μg/g), and the rest 88% had
very low FC values (<50 μg/g). The three patients with
elevated FC values used NSAIDs daily (Fig. 1). They also
presented with some functional gastrointestinal symp-
toms, but only one reported abdominal pain.
FC values related to disease characteristics, abdominal
pain, and NSAID usage
Patients with JIA had significantly more often elevated
FC value (p = 0.017) than arthralgia patients. The pres-
ence of ANA antibodies or HLA-B27 was not associated
with the elevation of FC, nor was the subtype of JIA.
In total, 27 (39%) of the 70 patients with JIA and 12
(60%) of the 20 with arthralgia experienced abdominal
pain (Figs. 1 and 2, Table 2). There was a linked associ-
ation between abdominal pain, elevated ESR values and
elevated FC values (overall p = 0.001). Of the 14 patients
(13 with JIA and one with arthralgia) with elevated FC
values (>100 μg/g, Tables 2 and 3), nine had abdominal
pains and six of them had elevated ESR values. In pa-
tients with an elevated ESR, anti-rheumatic treatment
was intensified which led to a decline of both the FC
and ESR (data not shown).
Of the 29 JIA patients on DMARDs who had FC
values of less than 50 μg/g, 11(38%) reported some ab-
dominal pain. All except one were girls, aged 5 to 15
years, and they all had a tendency to experience other
non-specific pains as well, such as limb pain and
headaches.
About half of the JIA patients (n = 34) used NSAIDs
regularly, and 15 (44%) of them reported abdominal
pains. Among the patients taking NSAIDs daily and ex-
periencing abdominal pain, one third had elevated FC
values >100μg/g (Fig. 1, Table 2). In the whole group of
90 patients, the use of NSAIDs was associated with ele-
vated FC levels (p = 0.03). Even though there was no
clear correlation between NSAID use and abdominal
pain, in many cases, abdominal pains lessened after low-
ering the NSAID dosage. At the same time the DMARD
medication of the JIA patients was intensified.
If the threshold of elevated FC value was lowered to
50 μg/g and a multivariate analysis made, the correlation
of NSAID use came more evident. Logistic regression
analysis showed that NSAID (OR = 3.96) and DMARD
(OR = 3.78) use together with abdominal pain (OR = 3.96)
were significantly (overall p = 0.046) correlated to the FC
elevation. Of these three parameters abdominal pain asso-
ciated most strongly to the elevated FC-value.
In the JIA group, 24% had an active joint disease. Dis-
ease activity was not associated with abdominal pain or
the elevated FC value (data not shown). None of the pa-
tients had celiac disease or food allergies; each child tol-
erated milk, except for two, one was lactose intolerant
and one with a cow’s milk allergy and Down’s syndrome.
Discussion
JIA patients who were on DMARDs had significantly
higher FC values than the other JIA patients, possibly
suggesting intestinal inflammation. The difference, how-
ever, seemed to be associated with NSAID use, too. The
higher FC values in those patients who used NSAIDs
regularly returned to normal after tapering the NSAID
dosage. Concurrently, in most JIA patients, DMARD
medication was also intensified. Thus, it can be specu-
lated that JIA patients may have some low activity also
in the intestinal mucosa when their joint disease is not
adequately controlled.
A recent comprehensive study in 44 adult spondyloar-
thritis (SpA) patients showed that FC can be elevated
even without obvious GI symptoms [25]. There are no
such studies of children. As reported in adults, the use
of NSAIDs may induce a modest increase in the FC
values, but rarely above 300 μg/g [26], which is in line
with our findings. In a recent study [27] of adult
rheumatoid arthritis (RA) and osteoarthritis (OA) pa-
tients using NSAIDs small intestinal lesions were identi-
fied significantly more often in RA (56.8%) patients
compared to OA (31.9%) suggesting a possible influence
of the underlying disease. They did not find any labora-
tory marker (hemoglobin, ESR, or fecal occult blood
test) to be used as a diagnostic factor but they did not
test FC. In our study the arthralgia patients had clearly
lower FC values suggesting also that the underlying dis-
ease might have an explanatory role and not only the
NSAID usage.
In our study most patients with higher FC values had
abdominal pain, but the presence of pain varied among
patients with lower FC values. The FC levels in patients
Fig. 2 Arthralgia patients with elevated FC-values and/or regular
NSAID use and/or abdominal pain. Of the 20 patients with arthralgia
12 had abdominal pain of which eight used NSAIDs (overlapping
areas). See text for details
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without GI problems were comparable to those observed
in healthy children [28]. However, our upper normal
limit (<100 μg/g) is somewhat higher when compared to
the manufacturer’s instructions (50 μg/g) and several
other studies with a different immunoassay [18, 28].
Since it has been suggested that pediatric patients having
FC values greater than 50μg/g should be monitored for a
possible flare-up of intestinal inflammation [28], we also
stratified the patient groups according to a lower cut-off
level for FC values (>50μg/g). With this lower cut-off
level, the JIA patients on NSAIDs showed significantly
more elevated values than other patients. These patients
with elevated FC values had significantly more often also
abdominal pain and DMARD medication.
When the joint disease was active patients took
NSAIDs more regularly, but as such, the presence of ac-
tive joint inflammation was not associated with an in-
crease in FC values. When the joint disease was
appropriately controlled and NSAIDs less often needed,
the patients did not report abdominal pain. Their FC
values were not elevated anymore in the control samples
taken approximately two months afterwards. The fact
that only five JIA patients in our study group were tak-
ing biological DMARDs indirectly shows that patients
using biologics have such a low disease activity that they
did not fulfill the criteria of this study (elevated ESR,
NSAID usage or abdominal pain). Also, in Finland, we
apply an aggressive step-down treating model [29] and
therefore, most of the JIA patients used DMARDS.
There is some evidence that biologics, especially etaner-
cept, could provoke the development of IBD [30]. While
three (out of five) of our patients on biologics used eta-
nercept and had low FC values, the number of patients
was too low to draw any conclusions. Recent reports
suggest that patients with SpA using etanercept confer a
risk of IBD [31], but we had no such patients.
All subgroups of JIA patients presented with compar-
able FC values, though the polyarthritis patients tended
to have higher values. These higher values in polyarthri-
tis patients were again mainly explained by NSAID use
in the active joint disease. Among HLA-B27 positive JIA
patients, there is a risk for evolution of IBD [32, 33], but
we did not find such patients with a suspicion of IBD.
Here, the proportion of HLA-B27 positive patients was
quite high, though in line with earlier studies from
Finland and the Nordic countries [34, 35]. In contrast, a
recent study reported higher FC levels among patients
with enthesitis-related arthritis (ERA, HLA-B27 positive
juvenile SpA) than among other JIA patients [36]. This
difference was not explained by NSAID use. However,
the study reported that only one out of nine ERA pa-
tients with abdominal pain had an elevated FC value
(>300 μg/g). In a recent pilot study with adult patients,
elevated FC levels (cut-off value >50 μg/g) were found in
41% (of 39) patients with ankylosing spondylitis [37]. In
a more recent study, the optimal cut-off value for FC de-
tecting bowel inflammation in patients with ankylosing
spondylitis was 85 μg/g [20]. In that study, the FC values
were higher in patients with NSAID use, but the associ-
ation with bowel inflammation remained after adjust-
ment for the drug use. These results may indicate that
ERA/SpA patients should be under careful observation
for possible gut damage. The present results in pediatric
patients do not support this suggestion because only
one HLA-B27 positive patient had FC value greater
than 100 μg/g. On the other hand, the total number of
HLA-B27 positive JIA patients was limited, and more
studies on this matter need to be conducted in children.
When the FC value is exceedingly high, endoscopies
are recommended, but with lower values (150–300 μg/g)
and minor abdominal symptoms modifying the medica-
tion and/or diet may be the primary options. One of our
JIA patients had a very high FC value, which declined
below the cut-off point after introducing medication for
esophagitis confirmed in endoscopy and adjusting the
dairy consumption. Endoscopies are invasive procedures
requiring anesthesia in pediatric patients with indica-
tions to be discussed with pediatric gastroenterologists.
Taken together, we found that those JIA patients who
needed NSAIDs for longer periods have often elevated
FC levels. Notably, this might be a sign of suboptimal
disease control. In adults e.g. chronic gastritis did not
cause an increase in FC values [38]. Whether an uncon-
trolled joint disease could increase the risk of gut in-
volvement remains to be seen in future studies. In the
present study, one fifth of the JIA patients had an ele-
vated FC value; none of them had signs of IBD, and only
a few of the patients fulfilled indications for an
endoscopy.
The fecal test was easy to carry out, and the patients
readily agreed to bring a sample with them. Some pa-
tients had abdominal pains but a low FC value; those pa-
tients also had other non-specific aches and joint pains
that could not be attributed to arthritis, representing the
possibility of a dysfunctional pain disorder [39]. For pa-
tients with low FC levels, patients taking NSAIDs and
patients experiencing minor pains, invasive and un-
necessary endoscopies could be avoided [40]. Abdominal
pains are common, and while another study found that
14–16% of 8-year-old Finnish children experience ab-
dominal pain [41], in our study approximately 44% of
the patients reported such pain. Notably, FC levels are
low among patients with functional abdominal pain [42].
Conclusions
To conclude, we recommend determining the FC values
of JIA patients who complain of abdominal pain or who
regularly take NSAIDs for several weeks. If the FC value
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is high and remains high when cutting down exposure
to NSAIDs, bowel examinations (endoscopies) should be
considered. As the FC test is reliable in ruling out intes-
tinal inflammation and can easily be repeated, it should
be used more often because it is a simple non-invasive
procedure for the patient.
Key messages
1) Fecal calprotectin, a surrogate marker of gut
inflammation, should be measured in JIA patients
complaining abdominal pain or using NSAIDs
regularly.
2) When the fecal calprotectin value is consistently
elevated, consider the need of endoscopies.
3) A fecal calprotectin test is a useful tool in screening
for the need of gastrointestinal investigations.
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